What is King Pharmaceuticals's EPS (diluted)?

King Pharmaceuticals (KG) reported EPS (diluted) of -$0.96 in Q1 2026.

How has King Pharmaceuticals's EPS (diluted) changed year-over-year?

King Pharmaceuticals's EPS (diluted) decreased by 585.7% year-over-year, from -$0.14 to -$0.96.

What does EPS (diluted) mean?

Net income divided by the weighted-average number of shares outstanding plus all potentially dilutive securities (stock options, convertibles, warrants). The most conservative EPS measure.

King Pharmaceuticals KG EPS (Diluted)

EPS (Diluted) at other companies

Arch Capital GroupACGL

$2.88+94.6%

Everest GroupEG

$16.21+231%

SiriusPointSPNT

$0.82+67.3%

Skyward Specialty Insurance Group, Inc.SKWD

$1.09+7.9%

Selective Insurance GroupSIGI

$1.58-10.2%

Tiptree Inc.TIPT

——

Other financials

Income statement

See full

Revenue$10.2M+1,112%

Net income-$7.4M-1,786%

Balance sheet

See full

Cash & equivalents$62.2M+1,724%

Total debt$176.7M—

Total equity$121.4M+2,773%

Total assets$964.2M—

Cash flow

See full

Operating cash flow-$15.1M-1,628%

Valuation

See full

Market cap$70.42M-71.3%

Enterprise value$184.93M-52.3%

P/E1.2×—

P/S1.6×-27.7×

Profitability

See full

Net margin131.5%—

Returns & leverage

See full

Return on equity90.8%—

Debt / equity1.5×—

Where this comes from

Reported directly by King Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:EarningsPerShareDiluted.

The official record: King Pharmaceuticals’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about King Pharmaceuticals's eps (diluted).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is King Pharmaceuticals's EPS (diluted)?: King Pharmaceuticals (KG) reported EPS (diluted) of -$0.96 in Q1 2026.
How has King Pharmaceuticals's EPS (diluted) changed year-over-year?: King Pharmaceuticals's EPS (diluted) decreased by 585.7% year-over-year, from -$0.14 to -$0.96.
What does EPS (diluted) mean?: Net income divided by the weighted-average number of shares outstanding plus all potentially dilutive securities (stock options, convertibles, warrants). The most conservative EPS measure.